JP2023538134A5 - - Google Patents

Info

Publication number
JP2023538134A5
JP2023538134A5 JP2023512710A JP2023512710A JP2023538134A5 JP 2023538134 A5 JP2023538134 A5 JP 2023538134A5 JP 2023512710 A JP2023512710 A JP 2023512710A JP 2023512710 A JP2023512710 A JP 2023512710A JP 2023538134 A5 JP2023538134 A5 JP 2023538134A5
Authority
JP
Japan
Prior art keywords
compound according
linker
compound
target
mannose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538134A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046984 external-priority patent/WO2022040580A1/en
Publication of JP2023538134A publication Critical patent/JP2023538134A/ja
Publication of JP2023538134A5 publication Critical patent/JP2023538134A5/ja
Pending legal-status Critical Current

Links

JP2023512710A 2020-08-21 2021-08-20 腫瘍関連マクロファージを標的とするための組成物及び方法 Pending JP2023538134A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068904P 2020-08-21 2020-08-21
US63/068,904 2020-08-21
PCT/US2021/046984 WO2022040580A1 (en) 2020-08-21 2021-08-20 Compositions and methods for targeting tumor-associated macrophages

Publications (2)

Publication Number Publication Date
JP2023538134A JP2023538134A (ja) 2023-09-06
JP2023538134A5 true JP2023538134A5 (enExample) 2024-08-27

Family

ID=80350585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512710A Pending JP2023538134A (ja) 2020-08-21 2021-08-20 腫瘍関連マクロファージを標的とするための組成物及び方法

Country Status (10)

Country Link
US (1) US20240009314A1 (enExample)
EP (1) EP4199936A4 (enExample)
JP (1) JP2023538134A (enExample)
KR (1) KR20230058086A (enExample)
CN (1) CN116723846A (enExample)
AU (1) AU2021327392A1 (enExample)
CA (1) CA3192041A1 (enExample)
IL (1) IL300787A (enExample)
MX (1) MX2023002038A (enExample)
WO (1) WO2022040580A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024178142A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2024178140A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
CN120857932A (zh) * 2023-02-22 2025-10-28 坚毅科学股份有限公司 用于靶向肿瘤相关巨噬细胞的组合物和方法
EP4669335A1 (en) * 2023-02-22 2025-12-31 Resolute Science, Inc. Compositions and Targeting Methods of Tumor-Associated Macrophages
WO2025029126A1 (ko) * 2023-08-03 2025-02-06 최종훈 산소가 담지된 나노리포좀 및 이의 용도
CN117503760A (zh) * 2023-10-20 2024-02-06 深圳大学 靶向kras g-四链体的吲哚类小分子在制备治疗三阴性乳腺癌药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178838B1 (en) * 1999-05-14 2004-09-29 The Regents of the University of California Macromolecular carrier based on dextran for drug and diagnostic agent delivery
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2016126910A1 (en) * 2015-02-04 2016-08-11 University Of South Florida Self-assembled targeted inclusion complexes for drug delivery
CN105343900B (zh) * 2015-09-16 2019-04-02 中国海洋大学 褐藻多糖为载体的淋巴靶向核磁造影剂及制备方法和应用
US20170333304A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel Particles, Compositions, and Methods
MX2019004029A (es) * 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
AU2018289581C1 (en) * 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS
WO2020018434A1 (en) * 2018-07-17 2020-01-23 Scripps Health Compositions and methods for disrupting a macrophage network
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
US20210145989A1 (en) * 2019-09-30 2021-05-20 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
EP4076540A4 (en) * 2020-07-08 2024-02-21 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof

Similar Documents

Publication Publication Date Title
JP2023538134A5 (enExample)
JP6257669B2 (ja) ヒト前立腺特異的膜抗原(psma)をターゲッティングするj591ミニボディおよびcysダイアボディならびにこれらを使用するための方法
DE69423908T2 (de) Antikörper gegen das carcinoembryonic antigen
Rudd et al. A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies
Russell et al. Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies
van Gog et al. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics
Kanazaki et al. Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging
Kim et al. Asialoglycoprotein-receptor-targeted hepatocyte imaging using 99mTc galactosylated chitosan
Gupta et al. 99mTc-methionine gold nanoparticles as a promising biomaterial for enhanced tumor imaging
Paganelli et al. Clinical application of the avidin-biotin system for tumor targeting
Ediriweera et al. Targeted and modular architectural polymers employing bioorthogonal chemistry for quantitative therapeutic delivery
CN116723846A (zh) 用于靶向肿瘤相关巨噬细胞的组合物和方法
Adumeau et al. Site-specific, platform-based conjugation strategy for the synthesis of dual-labeled immunoconjugates for bimodal PET/NIRF imaging of HER2-positive tumors
US20020009416A1 (en) Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
Hagemans et al. Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents
US20090098046A1 (en) Combination Cancer Therapy with Anti-PSMA Antibodies
Yao et al. Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer
CN112111269B (zh) 一种荧光和镥-177双标记生物分子及其制备方法与应用
WO2023048233A1 (ja) 腫瘍細胞を死滅させるための医薬
US20070072251A1 (en) In vivo imaging using peptide derivatives
US20100179303A1 (en) Site-specific conjugation of ligands to nanoparticles
US11298431B2 (en) Method for labeling radioisotope radiolabeling compound and kit comprising the same for labeling radioisotope
Syrigos et al. Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer
CN1315967A (zh) 双功能抗体及其在导向抗肿瘤剂中的应用
US11497821B2 (en) Method for labeling radioisotope, radiolabeling compounds using quinone compound and kit comprising the same for labeling radioisotope